1184296-78-3

Basic information

• Product Name: 4-bromo-N'-methylbenzimidohydrazide
• Synonyms: 4-bromo-N'-methylbenzimidohydrazide
• CAS NO: 1184296-78-3
• Molecular Weight: 228.091
• Mol File: 1184296-78-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-bromo-N'-methylbenzimidohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-N'-methylbenzimidohydrazide(1184296-78-3)
• EPA Substance Registry System: 4-bromo-N'-methylbenzimidohydrazide(1184296-78-3)

Safety Data

• Hazardous Substances Data: 1184296-78-3(Hazardous Substances Data)

Upstream product

• 60-34-4 methylhydrazine 
• 55368-83-7 4-bromo-benzimidic acid ethyl ester hydrochloride 
• 623-00-7 4-bromobenzenecarbonitrile 

Downstream Products

• 1184174-17-1 3-(4-bromo-phenyl)-1,5-dimethyl-1H-[1,2,4]triazole 
• 1184174-04-6 3-(4-bromophenyl)-1-methyl-1H-[1,2,4]triazole 
• 1184174-05-7 4-[4-(1-methyl-1H-[1,2,4]triazol-3-yl)-phenyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1184174-06-8 2-chloro-1-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)ethan-1-one 
• 1184173-73-6 (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide 
• 1184174-18-2 tert-butyl 4-[4-(1,5-dimethyl-1H-[1,2,4]triazol-3-yl)-phenyl]-3,6-dihydro-2H-pyridine-1-carboxylate 

Relevant articles and documents

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

The emergence and evolution of new immunological cancer therapies has sparked a rapidly growing interest in discovering novel pathways to treat cancer. Toward this aim, a novel series of pyrrolidine derivatives (compound 5) were identified as potent inhibitors of ERK1/2 with excellent kinase selectivity and dual mechanism of action but suffered from poor pharmacokinetics (PK). The challenge of PK was overcome by the discovery of a novel 3(S)-thiomethyl pyrrolidine analog 7. Lead optimization through focused structure-activity relationship led to the discovery of a clinical candidate MK-8353 suitable for twice daily oral dosing as a potential new cancer therapeutic.

COMPOUNDS THAT ARE ERK INHIBITORS

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydopyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.